The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE: BROKER RATINGS SUMMARY: Buy Wolseley, Sell Berkeley - Goldman

Wed, 29th Jun 2016 14:39

LONDON (Alliance News) - The following shares received analyst recommendations Monday afternoon and morning:
----------
FTSE 100
----------
GOLDMAN RAISES WOLSELEY TO 'BUY' ('NEUTRAL') - TARGET 4,226 (4,294) PENCE
----------
GOLDMAN CUTS BERKELEY GROUP TO 'SELL' ('NEUTRAL') - TARGET 2,110 (4,000) PENCE
----------
GOLDMAN CUTS PERSIMMON PRICE TARGET TO 1,269 (2,280) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS BARRATT DEVELOPMENTS PRICE TARGET TO 365 (698) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS TAYLOR WIMPEY PRICE TARGET TO 123 (231) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS TRAVIS PERKINS PRICE TARGET TO 1,452 (2,236) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS INTU PROPERTIES PRICE TARGET TO 314 (350) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS LAND SECURITIES PRICE TARGET TO 1,200 (1,410) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS HAMMERSON PRICE TARGET TO 670 (750) PENCE - 'BUY'
----------
GOLDMAN CUTS BRITISH LAND CO PRICE TARGET TO 736 (910) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS ARM HOLDINGS TO 'BUY' (CONVICTION BUY) - PRICE TARGET 1275 (1400) PENCE
----------
SHORE CAPITAL RAISES PROVIDENT FINANCIAL TO 'BUY' ('HOLD')
----------
GOLDMAN CUTS WHITBREAD PRICE TARGET TO 3,910 (4,490) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES INTERCONTINENTAL HOTELS TARGET TO 3,120 (3,090)P - 'NEUTRAL'
----------
GOLDMAN CUTS EASYJET TO 'BUY' ('CONVICTION BUY') - TARGET 1,310 (1,740) PENCE
----------
GOLDMAN RESUMES SHIRE WITH 'CONVICTION BUY LIST' - TARGET 6,300 PENCE
----------
GOLDMAN RAISES ASTRAZENECA PRICE TARGET TO 4000 (3700) PENCE - 'SELL'
----------
GOLDMAN RAISES RELX TARGET TO 1360 (1320) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES PEARSON PRICE TARGET TO 845 (800) PENCE - 'SELL'
----------
GOLDMAN CUTS INFORMA PRICE TARGET TO 836 (839) PENCE - 'CONVICTION BUY LIST'
----------
GOLDMAN CUTS ITV PRICE TARGET TO 198 (258) PENCE - 'BUY'
----------
GOLDMAN CUTS WPP PRICE TARGET TO 1,800 (1,860) PENCE - 'BUY'
----------
GOLDMAN CUTS SKY PRICE TARGET TO 1013 (1254) PENCE - 'BUY'
----------
GOLDMAN CUTS SCHRODERS PRICE TARGET TO 2,800 (3,400) PENCE - 'BUY'
----------
GOLDMAN CUTS VODAFONE PRICE TARGET TO 260 (265) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS BT GROUP PRICE TARGET TO 540 (650) PENCE - 'CONVICTION BUY LIST'
----------
FTSE 250
----------
GOLDMAN CUTS COUNTRYWIDE TO 'SELL' ('NEUTRAL') - TARGET 218 (465) PENCE
----------
GOLDMAN RAISES GREAT PORTLAND TO 'NEUTRAL' ('SELL') - TARGET 690 (850) PENCE
----------
GOLDMAN RAISES DERWENT LONDON TO 'BUY' ('NEUTRAL') - TARGET 3,100 (3,815) PENCE
----------
GOLDMAN CUTS CREST NICHOLSON TO 'NEUTRAL' ('CONVICTION BUY') CUTS PRICE TARGET TO 384 (755) PENCE
----------
GOLDMAN CUTS BELLWAY TO 'NEUTRAL' ('BUY') - TARGET 1,715 (3,590) PENCE
----------
GOLDMAN CUTS REDROW TO 'NEUTRAL' ('BUY') - TARGET 301 (595) PENCE
----------
GOLDMAN CUTS MCCARTHY & STONE PRICE TARGET TO 161 (275) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS BOVIS HOMES TO 'NEUTRAL' ('BUY') - TARGET 684 (1,320) PENCE
----------
GOLDMAN RAISES SHAFTESBURY PRICE TARGET TO 1,061 (1,026) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS SEGRO PRICE TARGET TO 475 (555) PENCE - 'BUY'
----------
GOLDMAN CUTS HOWDEN JOINERY GROUP PRICE TARGET TO 376 (515) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS AA PRICE TARGET TO 340 (390) PENCE - 'BUY'
----------
GOLDMAN CUTS WILLIAM HILL PRICE TARGET TO 310 (380) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS ASCENCIAL TARGET TO 269 (278) PENCE - 'BUY'
----------
GOLDMAN RAISES UBM PRICE TARGET TO 750,37 (690,70) PENCE - 'BUY'
----------
GOLDMAN CUTS TULLETT PREBON PRICE TARGET TO 315 (390) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS ICAP PRICE TARGET TO 460 (520) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS MAN GROUP PRICE TARGET TO 155 (200) PENCE - 'CONVICTION BUY LIST'
----------
GOLDMAN CUTS INTERMEDIATE CAPITAL PRICE TARGET TO 565 (685) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS ASHMORE GROUP PRICE TARGET TO 310 (325) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS ABERDEEN ASSET MANAG PRICE TARGET TO 270 (288) PENCE - 'NEUTRAL'
----------
MAIN MARKET AND AIM
----------
GOLDMAN CUTS SECURE INCOME TO 'NEUTRAL' ('BUY') - TARGET 308 (355) PENCE
----------
GOLDMAN CUTS DAILY MAIL PRICE TARGET TO 584 (628) PENCE - 'SELL'
----------
GOLDMAN CUTS FOXTONS TO 'SELL' ('NEUTRAL') - TARGET 96 (198) PENCE
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.